Industry Research

  1. Top 10 Reasons For Oral Dose CMO Preference 12/1/2023

    Just under one-third of respondents who participated in ISR’s Oral Dosage Forms Market Outlook research shared that Familiarity/History of working together/Prior positive experience are the reasons behind their preferences.

  2. CDMO Engagement Timeline For Gene Therapy 11/1/2023

    In ISR’s inaugural Gene Therapy CDMO Benchmarking Report, we asked respondents to identify the stage in which their company would typically engage a CDMO to support their gene therapy manufacturing needs.

  3. Sterile Injectable Life Cycle Management 10/2/2023

    In a recent study on the market outlook for sterile injectable drug product manufacturing, ISR asked respondents whether their company is investigating improving or extending the life cycle of sterile injectable drug products in their portfolio.

  4. How Do Outsourcers Feel About The CDMO Industry? 10/2/2023

    Now is the time for company leaders at all stages to evaluate insurance costs, which can be among the top five most significant budget line items.

  5. Benefits Of Clinical Development Outsourcing Models 9/1/2023

    ISR’s Clinical Development Outsourcing Models (5th Edition) report examines three outsourcing models commonly used in the clinical trial space. Respondents provided feedback on the benefits of each outsourcing strategy currently used at their company.

  6. Which CDMO Traits Predict Sponsor Loyalty When Outsourcing Small Molecule API? 8/1/2023

    Using data from Industry Standard Research’s Small Molecule API CDMO Benchmarking report, ISR ran a regression analysis to identify which contract manufacturer characteristics are most-closely related to sponsor loyalty.

  7. Cell & Gene Therapies Manufacturing Market Outlook 8/1/2023

    In ISR’s Cell & Gene Therapies Manufacturing Market Outlook (2nd Edition) research participants were asked to select the cell and gene manufacturing activities their company would outsource to CDMOs in the next 18 months and in five years.

  8. Cell & Gene Therapies Manufacturing Market Outlook 7/3/2023

    In ISR’s Cell & Gene Therapies Manufacturing Market Outlook (2nd Edition), we asked respondents to rank their top three satisfaction drivers regarding a CDMO’s performance in cell and/or gene manufacturing activities.

  9. Attributes Gaining Importance When Selecting Among Preferred Providers For Phase 1 Services 6/1/2023

    The service provider selection process is a complicated one. Many factors come into play during this process. One critical factor is undoubtedly the presence of preferred provider agreements. Companies can spend a great deal of time negotiating these agreements, and their presence, or lack thereof, can make or break which CROs are shortlisted or awarded a Phase 1 study.

  10. Clinical Manufacturing Market Outlook 5/1/2023

    In ISR’s Clinical Manufacturing Market Outlook report, we asked sponsors about their top reasons for being satisfied with an outsourced clinical trial manufacturing project.